Linear Particle Accelerators Market Analysis

Linear Particle Accelerators Market Analysis

To get key market trends

  Download Free Sample

Based on product type, the market is segmented into high-energy machine, medium-energy machine, and low-energy machine. The high energy machine segment held the majority of market share in 2023 and is anticipated to grow at CAGR of 6.3% over the forecast period.
 

• The leading share of high energy machine can be attributed to their prevalent use for treating a wide range of cancers that are located in deep seated areas such as pelvis, abdomen, and thorax. High energy machine also enables value-based care as they can penetrate deep into tissues and facilitate higher radiation doses to tumors, thereby resulting into fewer sessions of radiotherapy.
   
• Moreover, increasing availability of high-energy linear particle accelerators integrated with advanced imaging systems such as magnetic resonance imaging, and positron emission tomography is enabling precise imaging and real-time monitoring during treatment. As a result, the demand for high energy linear particle accelerators is increasing globally.
   

Based on technology, the linear particle accelerators market is classified into X-ray, electron, proton, ion beam, and other technologies. The X-ray segment dominated the market with a revenue of about USD 1.1 billion in 2023.
 

• Leading share of conventional linear particle accelerator segment can be attributed to their increasing use in advanced linear particle accelerators such as intensity-modulated radiation therapy, volumetric modulated arc therapy, and stereotactic radiosurgery & stereotactic body radiotherapy. Achieving the desired dose distribution to target the tumor effectively while protecting surrounding healthy tissues necessitates the accurate delivery of X-rays using these techniques.
   
• Additionally, cost effectiveness of X-ray radiotherapies has also resulted in a dominating share of the segment. Advanced radiotherapies such as Proton therapies cost twice the X-ray radiotherapies. Furthermore, the versatility and effectiveness of x-ray therapy make it cost-effective in the long run for end users, which adds to the high market share of X-ray segment.
   

Based on treatment type, the linear particle accelerators market is classified into conventional linear particle accelerator, stereotactic radiosurgery & stereotactic body radiotherapy, intensity-modulated radiation therapy, volumetric modulated arc therapy, image-guided radiation therapy, and other treatment types. The conventional linear particle accelerator segment dominated the market with a revenue of about USD 1 billion in 2023.
 

• Leading share of the conventional linear particle accelerators segment can be attributed to their longstanding presence and the trust these devices have developed across radiotherapists in terms of safety, reliability, and effectiveness in cancer treatment.
   
• Moreover, availability of advanced conventional linear particle accelerators with enhanced features such as integration of AI for treatment planning and integration of advanced imaging techniques is also contributing to their higher adoption globally.
   

Based on application, the linear particle accelerators market is classified into prostate cancers, breast cancers, lung cancers, colorectal cancers, head & neck cancers, and other applications. The prostate cancer segment dominated the market with a revenue of about USD 904.3 million in 2023.
 

• Leading share of prostate cancer segment can be attributed to their high incidence globally. For instance, according to the World Cancer Research Fund International, prostate cancer was the second most common cancer in 2020. The high incidence and prevalence of this disease increases the demand for effective treatment options, including radiation therapy using linear particle accelerators.

• Furthermore, radiation therapy has proven to be a well-established and effective treatment for prostate cancer, particularly in early-stage and localized cases, and offers a non-invasive alternative to surgical interventions. As a result, the adoption of linear particle accelerator in treatment prostate cancer is high.
   

Based on end-user, the linear particle accelerators market is classified into hospitals, radiology clinics, and other end users. The hospitals segment secured a leading share of about 62.2% in 2023 and is anticipated to grow at 5.7% CAGR during the forecast period.
 

• Large hospitals and the hospitals associated with universities or research institutions often have better access to funding and financial resources. This helps them to invest in latest and advanced linear particle accelerators that require high initial investments.
   
• Moreover, hospitals are among the preferred settings for radiotherapies as they have specialized departments for providing oncology treatments equipped with latest equipment and skilled healthcare professionals including radiation oncologists and surgical oncologists. This helps hospitals to provide comprehensive patient care, making them the preferred destination for radiation therapy.
   

North America linear particle accelerators market accounted for 41.1% of market share in global market in 2023 and is predicted to reach USD 1.8 billion by 2032.
 

• Increasing demand for radiotherapy treatment is driving the adoption of linear particle accelerators in North America. According to the 2022 article by GE HealthCare, about 1 million cancer patients received radiation therapy in 2022 in the U.S.  
   
• Moreover, North America, particularly the United States and Canada, boasts advanced radiotherapy centers that are well equipped with advanced linear particle accelerators such as stereotactic radiosurgery & stereotactic body radiotherapy systems and volumetric modulated arc therapy systems.
   
• Furthermore, presence of large number of established vendors in the region offering advanced linear particle accelerators is also contributing to the revenue growth in the region. These vendors have a well-established distribution network in the region along with extensive and experienced team for offering efficient maintenance services.
   

The U.S. linear particle accelerators market was valued at USD 985.1 million in 2023 and is anticipated to grow at a CAGR of 5.7% over the forecast period.
 

• Increasing demand for linear particle accelerators to perform advanced radiotherapies is driving the demand for linear particle accelerator in U.S. According to a November 2022 article from GE Healthcare, U.S. had presence of about 13 linear particle accelerators for every 1 million patients. To provide improved access for radiation therapy, the end users are expected to procure an increasing number of advanced linear particle accelerators during the forecast period. This is expected to contribute to the overall revenue growth in the market.
   
• Increasing incidence of cancer in the U.S. is also contributing to an increasing demand for radiotherapy, thereby driving the revenue growth in the market. For instance, according to the American Cancer Society, in 2023 about 1.9 million new cancer incidences were recorded, with an overall 5% year on year increase in prostate cancer during 2014-2019.
   

Germany linear particle accelerators market is expected to show lucrative growth during the forecast period.
 

• Presence of large number of radiotherapy centers in the country is driving the revenue growth in the linear particle accelerator market in Germany. According to a study published by Springer Link in September 2021, Germany has the highest number of radiotherapy centers (283) in Europe, followed by France (177).
   
• Moreover, presence of efficient reimbursement coverage for radiotherapy in Germany is also driving the demand for radiotherapy. Reimbursement for radiotherapy in Germany primarily involves a fixed fee for treatment planning and patient setup, along with payment per fraction, that offers simplicity and transparency in reimbursement process.
   

India linear particle accelerators market is anticipated to grow remarkably over the coming years.
 

• Increasing prevalence of cancer in India is driving increasing burden on cancer care facilities. According to a December 2022 study published by National Center for Biotechnology Information, the country had the presence of only 546 linear particle accelerators on 1.4 billion population. Owing to an increasing demand for radiotherapy in India, the radiation therapy centers are expected to procure increasing number of linear particle accelerators to provide enhanced patient care, which is expected to contribute to the overall growth of the market.
   
• Moreover, government of India is promoting the use of advanced therapies such as radiation therapies through programs such as “First Cancer Care” and “Megh CAN Care”, which is contributing to an increased demand for linear particle accelerators in the country.